Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADMIRE-CD II
2017-000725-12Phase 3Completed
- Sponsor
- TiGenix
- Start
- Apr 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease and anal fistula comparing Cx601 with Placebo (2 arms). Primary endpoint: Combined remission at Week 24. Started Apr 2017; status: completed.
02
Drugs
darvadstrocel
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on 2017-000725-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000725-12.